ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Resistances to immunotherapies remains a major hurdle towards a cure for melanoma in numerous patients. An increase in the mesenchymal phenotype and a loss of differentiation have been clearly associated with resistance to targeted therapies. Similar phenotypes have been more recently also linked to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Cheli, Yann, Tulic, Meri K., El Hachem, Najla, Nottet, Nicolas, Jacquel, Arnaud, Gesson, Maeva, Strub, Thomas, Bille, Karine, Picard-Gauci, Alexandra, Montaudié, Henri, Beranger, Guillaume E., Passeron, Thierry, Close, Pierre, Bertolotto, Corine, Ballotti, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7789764/
https://ncbi.nlm.nih.gov/pubmed/33413419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-020-01306-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados